The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic treatment against stroke and systemic embolism (Stroke Prevention in Atrial Fibrillation) will be observed.
The study takes place in Korea and Taiwan. Approximately a total of 1200 patients will be included in the study within 12 months. The observation period for each patient is 1 year from enrollment into the study, or until withdrawal of consent or lost to follow-up. Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.
- Rivaroxaban (Xarelto, BAY59-7939) Drug
Intervention Desc: Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function ARM 1: Kind: Experimental Label: Treatment-naïve NVAF patients in Korea and Taiwan Description: Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions
Patients from Taiwan and Korea visiting doctors in hospitals or medical practices for treatment of atrial fibrillation
|Type||Measure||Time Frame||Safety Issue|
|Primary||Major bleeding events, collected as Serious Adverse Events (SAEs) or non-serious Adverse Events (AEs)||Up to one year|
|Secondary||AEs||Up to one year|
|Secondary||SAEs||Up to one year|
|Secondary||All-cause mortality||Up to one year|
|Secondary||Non-major bleeding events||Up to one year|
|Secondary||Symptomatic thromboembolic events||Up to one year|
|Secondary||Start of rivaroxaban therapy and, if applicable, stop of rivaroxaban therapy||Up to one year|